Td Asset Management Inc Uni Qure N.V. Transaction History

Td Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$11.12 - $22.2 $199,048 - $397,380	17,900 New	17,900 $205,000
Q2 2022 Aug 04, 2022	BUY	$13.15 - $20.45 $9,205 - $14,315	700 Added 2.14%	33,378 $622,000
Q4 2021 Feb 10, 2022	SELL	$20.24 - $36.01 $269,192 - $478,933	-13,300 Reduced 28.93%	32,678 $678,000
Q2 2021 Aug 11, 2021	SELL	$29.97 - $37.17 $170,829 - $211,869	-5,700 Reduced 11.03%	45,978 $1.33 Million
Q1 2021 May 14, 2021	BUY	$29.24 - $42.03 $347,312 - $499,232	11,878 Added 29.84%	51,678 $1.74 Million
Q4 2020 Feb 16, 2021	BUY	$35.35 - $50.67 $498,435 - $714,447	14,100 Added 54.86%	39,800 $1.44 Million
Q3 2020 Nov 10, 2020	BUY	$35.98 - $47.66 $420,965 - $557,622	11,700 Added 83.57%	25,700 $947,000
Q2 2020 Aug 13, 2020	BUY	$45.06 - $67.74 $162,216 - $243,863	3,600 Added 34.62%	14,000 $631,000
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $224,056 - $414,232	5,600 Added 116.67%	10,400 $493,000
Q4 2019 Feb 11, 2020	BUY	$37.13 - $74.62 $178,224 - $358,176	4,800 New	4,800 $344,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.